Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company achieved a revenue of 1.77 billion yuan in the first half of 2025, representing a year-on-year growth of 30.8%, while the net profit attributable to shareholders grew by only 5.2% [5] - The slower profit growth compared to revenue is attributed to increased sales expenses [9] - The company plans to distribute a cash dividend of 0.25 yuan per share, corresponding to a payout ratio of 54% for the first half of the year [5] Revenue Performance - The company's two main brands, Marubi and Lianhuo, saw revenue growth of 34% and 24% respectively, with online channel revenue increasing by 38% [6] - For the first half of 2025, Marubi brand revenue was 1.25 billion yuan, accounting for 71% of total revenue, while Lianhuo brand revenue was 520 million yuan, making up 29% [6] Financial Metrics - The gross margin for the first half of 2025 slightly decreased by 0.1 percentage points to 74.6% [7] - The operating cash flow significantly increased by 97.4% year-on-year to 120 million yuan [8] - The company’s inventory as of June 2025 increased by 35.9% year-on-year to 240 million yuan [8] Profitability and Valuation - The report projects a downward revision of the net profit forecast for 2025 to 390 million yuan, reflecting a 13% decrease from previous estimates [9] - The current stock price corresponds to a price-to-earnings (P/E) ratio of 46 for 2025 [9] Future Projections - The company is expected to achieve a revenue of 3.75 billion yuan in 2025, with a growth rate of 26.3% [10] - The projected net profit for 2025 is 393 million yuan, with a growth rate of 15.1% [10]
丸美生物(603983):2025 年中报点评:收入增长靓丽,费用增加致利润增速不及预期